InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
4
T+90 hit rate
67%
T+90 mean return
+23.8%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Aguilar-Cordova Estuardo, Directeur Scientifique. Officer active across 1 company, notably Candel Therapeutics, Inc.. In total, 18 reports have been published. Split: 0 buy · 4 sells. Total volume traded: €263k. History available since 6 May 2022. The latest transaction was filed on 21 February 2025 (Disposition). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
10,582 shares@ US$12.022.9% of flowCADLSEC:0001873919-25-000002:0
10,583 shares@ US$12.022.9% of flowCADLSEC:0001873919-25-000002:1
31,335 shares@ US$8.616.2% of flowCADLSEC:0001873919-25-000001:0
50,000 shares@ US$9.0110.3% of flowCADLSEC:0001873919-24-000011:0
100,000 shares@ US$9.0020.6% of flowCADLSEC:0001873919-24-000010:0
200,000 shares@ US$8.5338.5% of flowCADLSEC:0001873919-24-000009:0
20,000 shares@ US$4.462.0% of flowCADLSEC:0001873919-24-000008:0
20,000 shares@ US$4.972.3% of flowCADLSEC:0001873919-24-000006:0
7,500 shares@ US$5.330.9% of flowCADLSEC:0001873919-24-000005:0
6,000 shares@ US$5.380.7% of flowCADLSEC:0001873919-24-000004:0
16,427 shares@ US$5.532.0% of flowCADLSEC:0001873919-24-000003:0
15,000 shares@ US$6.052.0% of flowCADLSEC:0001873919-24-000002:0
15,000 shares@ US$6.022.0% of flowCADLSEC:0001873919-24-000002:1
10,412 shares@ US$6.031.4% of flowCADLSEC:0001873919-24-000002:2
6,214 shares@ US$7.00910.9% of flowCADLSEC:0001873919-24-000001:0
135,183 shares@ US$1.460.060% mcap100.0% of flowCommon StockSEC:0000899243-22-017474:0
162,137 sharesCommon StockSEC:0000899243-21-031103:0
162,137 sharesCommon StockSEC:0000899243-21-031103
18 of 18 declarations
About Aguilar-Cordova Estuardo
Estuardo Aguilar-Cordova is the Chief Scientific Officer of Candel Therapeutics, Inc. In this role, he oversees the company's research and development initiatives, focusing on innovation and the advancement of therapies. His responsibilities include leading scientific teams and collaborating with other departments to ensure that research projects align with the company's strategic objectives.
